Sevoflurane is an inhaled general anaesthetic featured with rapid induction and quick wake-up of patients. It has slight inhibition on circulation, little effect on liver and kidney function and a clear myocardial protective effect. Therefore, sevoflurane has now become the main inhaled anaesthetic and is particularly suitable for patients with myocardial damage.
According to the analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently Abbott holds a very small market share. The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter of the United States. In 2007 and 2008, CFDA approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China. Gradually, domestic sevoflurane dominates the Chinese market.
As the environmental pollution intensifies and the population ages, the demand for medical services is rapidly rising. The hospitalization increased from 115 million in 2008 to 227 million in 2016, with the CAGR up to 7.8%. Among them, one quarter of patients was hospitalized for surgery. The increasing amount of surgery boosts the demand for narcotic drugs.
The market research shows that the sales value of sevoflurane in the Chinese market rose from less than CNY 4 million in 2005 to CNY 82.8 million in 2007 and to CNY 633 million in 2017. The CAGR during 2007 to 2017 reached about 22.6%.
According to the market research, the major market share holders in China are Maruishi, Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Baxter, MARUKO and Lunan Better Pharmaceutical Co., Ltd. In terms of sales volume, Shanghai Hengrui Pharmaceutical holds the biggest market occupancy, which in 2017 was about 55%.
It is expected that with the increasing surgery in China from 2018 to 2022, the demand for narcotic drugs will continue to increase, creating a promising future market for sevoflurane.
- Indication of sevoflurane
- Market size of sevoflurane
- Major sevoflurane manufacturers in the Chinese market
- Competition pattern of sevoflurane in China
- Sale price of sevoflurane in China
- Prospects of sevoflurane
1 Sevoflurane-related Concepts
1.2 Development of Sevoflurane in Chinese Market
2 Market Overview of Sevoflurane
2.1 Patents and Drug Approval of Government
2.2 Major Manufacturers
2.3 Market Size
3 Analysis of Sevoflurane Sales in China, 2013-2017
3.1 Sales Value
3.1.1 Overall Sales
3.1.2 Sales Value in Different Regions
3.2 Sales Volume
3.2.1 Overall Volume
3.2.2 Sales Volume by Region
3.3 Market Share of Sevoflurane by Dosage Form
3.3.1 Market Share of Sevoflurane by Sales Value
3.3.2 Market Share of Sevoflurane by Sales Volume
4 Market Share of Sevoflurane Manufacturers in China, 2013-2017
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Major Sevoflurane Manufacturers in Chinese Market, 2017-2018
5.2 Shanghai Hengrui Pharmaceutical Co., Ltd.
5.3 Jiangsu Hengrui Medicine Co., Ltd.
5.5 Maruko Pharmaceutical Co., Ltd.
5.6 Lunan Better Pharmaceutical Co., Ltd.
6 Reference Sale Price of Sevoflurane Manufacturers in Hospitals, 2017-2018
6.2 Shanghai Hengrui Pharmaceutical Co., Ltd.
6.3 Jiangsu Hengrui Medicine Co., Ltd.
6.5 Maruko Pharmaceutical Co., Ltd.
6.6 Lunan Better Pharmaceutical Co., Ltd.
7 Prospects of Sevoflurane in China, 2018-2022
7.1 Forecast on Market Size
7.2 Market Prospects
Part of Charts
Chart Drug Approval of Government on Sevoflurane in China
Chart Sales of Sevoflurane in China
Chart Sales Value of Sevoflurane in China, 2007-2017
Chart Sales volume of Sevoflurane in China, 2007-2017
Chart Market Share of Top 6 Sevoflurane Manufacturers in Sales Value, 2013-2017
Chart Market Share and Sales Value of Maruishi in China, 2013-2017
Chart Market Share and Sales Value of Shanghai Hengrui Pharmaceutical in China, 2013-2017
Chart Market Share and Sales Value of BAXTER in China, 2013-2017
Chart Sevoflurane Sale Price of Maruishi in Several Chinese Cities, 2017-2018
Chart Sevoflurane Sale Price of Shanghai Hengrui Pharmaceutical in Several Chinese Cities, 2017-2018
Chart Sevoflurane Sale Price of Jiangsu Hengrui Medicine in Several Chinese Cities, 2017-2018
Chart Forecast on Sevoflurane Market Size in China, 2018-2022
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.